The main component of injections used to treat diabetes and aid in weight loss is semaglutide.
The study discovered that individuals with diabetes who were taken semaglutide had a four-fold increased risk of being diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION).
In the meantime, the likelihood of developing the illness was more than seven times higher in those who were prescribed the meds and overweight or obese compared to those using conventional weight-loss medications.
NAION is a rare condition that arises from diminished or obstructed blood flow to the optic nerve.
People usually experience an abrupt loss of vision in one eye.
NAION is now incurable, and vision frequently does not get better.
Leading the new study was Joseph Rizzo, an ophthalmology professor at Harvard Medical School in the United States; the work was published in JAMA Ophthalmology.
He claimed that although drug use has “exploded,” physicians should go over the possible danger of NAION with their patients going forward.
